Скачать или смотреть (Part 14) - Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus

⚡ All three second-line drugs work about the same ⚡
The ESETT trial compared fosphenytoin, levetiracetam, and valproate head-to-head in benzodiazepine-refractory status epilepticus—and found no clear winner.
The Backstory: After benzos, what’s next in SE? Practice varied widely, with little direct evidence.
What They Did:
✅ 384 patients with convulsive SE persisting after benzos
✅ Randomized to fosphenytoin, levetiracetam, or valproate
✅ Primary outcome: seizure cessation without further meds by 60 minutes
The Results That Mattered:
🏆 ~45% success across all three arms
🏆 No major differences in safety or efficacy
Why This Matters: All three are reasonable—choice depends on comorbidities, availability, and side-effect profile.
Clinical Impact:
• Stock all three and tailor choice by patient profile
• Protocolize dosing and monitoring
The Lesson: It’s not which drug—it’s getting it in fast.
Do you have an SE protocol that ensures timely second-line treatment? 🤔
👆 Follow for epilepsy emergency updates | Share with your ED team | Visit NowyouknowNeuro.com for the full summary
#Neurology #StatusEpilepticus #ESETT #SeizureEmergency #EvidenceBasedMedicine

[Links]

NowYouKnow Neuro: https://www.nowyouknowneuro.com/
Subscribe: https://www.nowyouknowneuro.com/sign-...
Instagram: NowyouknowNeuro